An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole

International Journal of Clinical Practice

Volumn 56, Issue 2, 2002, Pages 132-139

  Bown, R L ^a  

^a FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CELECOXIB; CLARITHROMYCIN; DIAZEPAM; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; IBUPROFEN; INDOMETACIN; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PARACETAMOL; PENTAGASTRIN; PHENYTOIN; PLACEBO; PREDNISOLONE; PROPRANOLOL; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROXITHROMYCIN; TERFENADINE; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DUODENUM ULCER; DYSPEPSIA; ENZYME INHIBITION; ERADICATION THERAPY; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; MALE; NAUSEA; PRIORITY JOURNAL; SKIN DISEASE; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; STOMACH ULCER; VERTIGO;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; DIGESTIVE SYSTEM DISEASES; DUODENAL ULCER; DYSPEPSIA; ENZYME INHIBITORS; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HUMANS; OMEPRAZOLE; STOMACH ULCER; ZOLLINGER-ELLISON SYNDROME;

EID: 0036119175     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion: A placebo-controlled study in healthy volunteers
2. Lansoprazole achieves faster control of intragastric acidity than rabeprazole within the first 5 hours of administration
3. Lansoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion
4. The effects of oral doses of lansoprazole and omeprazole on gastric pH
5. Rapid effect of lansoprazole on intragastric pH: A crossover comparison with omeprazole
6. Twenty-four-hour monitoring of intragastric acidity: Comparison between lansoprazole 30 mg and pantoprazole 40 mg
7. Lansoprazole: Which PPI provides faster and more profound acid suppression?
8. Effect of lansoprazole on physiologic esophageal acid reflux
9. Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia
10. Speed of heartburn relief: Lansoprazole vs omeprazole
11. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice
12. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis: Results of a Scandinavian multicentre trial
13. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis
14. Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole
15. Lansoprazole: An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders
16. Review article: Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors
17. Pharmacokinetics of lansoprazole in adolescent patients with gastroesophageal reflux disease (GERD)
18. Lansoprazole in children: Pharmacokinetics and efficacy in reflux oesophagitis
19. Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin
20. Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment
21. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline
22. Lack of a pharmacokinetic interaction between lansoprazole of pantoprazole and theophylline
23. Pharmacokinetic interaction between proton pump inhibitors and roxithromycin in volunteers
24. Pharmacokinetic interaction between acetaminophen and lansoprazole
25. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin when given single and concomitant
26. Effect of lansoprazole (L) on the steady state pharmacokinetics of metronidazole (M) following concomitant administration of both drugs in 24 healthy volunteers
27. Clinical effectiveness of lansoprazole in patients with gastric ulcers: Evaluation of quality of ulcer healing based on endoscopic ultrasonographic findings
28. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia
29. Current concepts in the management of Helicobacter pylori infection
30. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection
31. Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori
32. Lansoprazole and amoxicillin and clarithromycin on H. pylori eradication. Comparison of 7, 10 and 14 days treatment
33. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: An Asian multicentre double-blind randomised placebo controlled study
34. Cost effectiveness of Helicobacter pylori eradication in patients with duodenal ulce: An analysis of triple therapy versus two dual therapy alternatives
35. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: Results of a double-blind, randomized, multicenter study
36. Healing and prevention of NSAID-associated ulcers in patients continuing to take NSAIDs: Lansoprazole vs ranitidine and lansoprazole vs misoprostol vs placebo
37. PPI based healing of NSAID-associated ulcers in patients continuing NSAIDs
38. Effect of H. pylori status on healing of gastric ulcer patients continuing to take NSAIDs and treated with lansoprazole or ranitidine
39. Lansoprazole heals NSAID-associated gastric ulcers despite H. pylori infection and continued NSAID use
40. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in NSAIDs users
41. COX-2 inhibitor compared with proton pump inhibitor in the prevention of recurrent ulcer complications in high risk patients taking NSAIDS
42. Lansoprazole provides superior symptom relief for patients with non-erosive reflux esophagitis
43. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial)
44. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis
45. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis
46. Lansoprazole (30 mg) is more effective than high-dose ranitidine (2×300 mg): A Dutch multi-centre trial
47. Lansoprazole versus famotidine in symptomatic reflux esophagitis: A randomised multicenter study
48. Efficacy and safety of lansoprazole 15 mg OaD or 30 mg OaD as one year maintenance treatment for erosive reflux esophagitis: A radomized trial
49. Lansoprazole maintains healing in patients with reflux esophagitis
50. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole
51. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis
52. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis
53. Lansoprazole versus omeprazole in long term maintenance treatment of reflux oesophagitis: A Scandinavian multicentre trial
54. Low dose lansoprazole is significantly superior to omeprazole in the prevention of relapse in patients with mild to moderate reflux oesophagitis
55. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: A randomised controlled study
56. Adolescent patients with gastroesophageal reflux disease; results from a randomised trial of lansoprazole
57. Efficacy of lansoprazole in the treatment of GERD in children
58. Lansoprazole in the treatment of gastro-oesophageal reflux disease in children
59. Efficacy of lansoprazole 30 mg versus omeprazole for 21 days treatment of acute esophagitis
60. 2-receptor antagonists: Standard therapy for acid-peptic diseases (second of two parts)
61. Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs: An analysis of randomised clinical trials
62. +-ATPase inhibitor: A controlled, double-blind study
63. 2-RA therapy
64. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine
65. Prospective study of the long-term efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome
66. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome
67. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome
68. Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome: First six months of treatment
69. Safety of lansoprazole
70. Safety profile of lansoprazole. The US clinical trial experience
71. A prospective follow-up study of 5669 users of lansoprazole in daily practice
72. Safety review in 10,008 users of lansoprazole in daily practice
73. Treatment of Helicobacter pylori infection in clinical practice in the United States: Results from 224 patients
74. One week triple therapy for Helicobacter pylori: A multicentre comparative study
75. Safety of lansoprazole in the treatment of GERD in children
76. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole
77. Cost-effective management strategies for acid-peptic disorders
78. Impact of lansoprazole in the management of gastroesophageal reflux disease (GERD): A costly-utility analysis
79. 2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis
80. 2RA) and placebo in patients with non-ulcer dyspepsia (NUD)
81. An economic comparison of Helicobacter pylori treatment regimens in Canada